Kim Brøsen

[vc_row][vc_column width=”1/4″]Kim Brøsen
[/vc_column][vc_column width=”3/4″]

Professor Kim Brøsen, Denmark

Kim Brøsen has been a towering presence within European clinical pharmacology for more than 30 years. Kim Brøsen is internationally recognized as an innovative, pioneering and leading researcher within human drug metabolism and pharmacogenomics. Kim Brøsen has been a strong developer and promoter of clinical pharmacology training and he has tirelessly pursued the implementation of clinical pharmacology as a medical speciality with a recognizable and respected professional identity. Kim Brøsen has an elite publication record and resides deservedly among the Highly Cited Researchers within clinical pharmacology. He is known for his strong strategic competences and his ability to create and nurse national and international networks. Not least, he is known for his inspiration and support to young researchers and Kim Brøsen is genuinely appreciated for his overall academic and social generosity.

[/vc_column][/vc_row]

[vc_row][vc_column]
[wm_tabs active=”1″ ]

[wm_item title=”Nomination Letter”]

Biography

Kim Brøsen was born in Copenhagen on the 30 July 1954 and graduated from Medical School,University of Copenhagen in 1981. After 4 years of hospital internship, he became a research fellowat Clinical Pharmacology, Odense University (now University of Southern Denmark) in 1985. Heeffortlessly proceeded through the academic ranks as assistant professor/lecturer (1986) associateprofessor/senior lecturer (1988) and was appointed to his current position as full professor inclinical pharmacology in 1995 at the age of 41.Kim Brøsen was a guest researcher from 1988-89 at Biozentrum of the University of Basel,Switzerland, and professeur associé from 2002-03 at Service de Pharmacologie, Hospital Saint-Antoine, Paris, FranceKim Brøsen received specialist authorization as a clinical pharmacologist in 1997 and wasappointed a consultant at Odense University Hospital the same year. In 2000, he was appointedhead of research in clinical pharmacology at University of Southern Denmark.

Professional accomplishments

Kim Brøsen has been a relentless promotor of clinical pharmacology within hospital health caresettings. He insists that clinical pharmacology should primarily be practiced with a focus on patientrelated outcomes and should strive to provide true improvement to health care. Kim Brøsen hasbeen essential to the development of clinical pharmacology as a medical speciality in Denmark andEurope – an effort that he continuously pursues. He has been the driving force/member/president ofseveral local and regional drug committees and has established systematic initiatives to supportrational pharmacotherapy at the patient level. Kim Brøsen was one of the architects behind theestablishment of the drug information in Denmark (a service that provides invaluable evidencebasedguidance to clinicians and health care personnel alike). In 2010 he was the main driving forcebehind the establishment of a Pharmacy Bachelor and Master Program, University of Southern Denmark.In his capacity as head of research for the Department of Clinical Pharmacology at University of Southern Denmark, he has established a vibrant, lively and productive research environment, highly appreciated among colleagues, young researchers, secretaries and laboratory personal alike.

Awards and services

  • Kim Brøsen was awarded the Ole J. Rafaelsen prize in 1991 and the Norwegian Poulsson prize in 2005.
  • Kim Brøsen has been the editor-in chief of Basic & Clinical Pharmacology and Toxicology since 2003 (formerly Pharmacology & Toxicology).
  • Kim Brøsen has been the editor of the major clinical pharmacology reference book in Denmark, [Basic and Clinical Pharmacology], and principal editor for its latest two editions.
  • Kim Brøsen was editor of “A Guide to Training in Clinical Pharmacology in Europe” (1999) and he co-authored the position paper “Clinical Pharmacology in Health Care, Teaching and Research” (2012) published by WHO, CIOMS and IUPHAR.
  • Kim Brøsen has served as board member, secretary and president of the Danish Society of Clinical Pharmacology.
  • Kim Brøsen was a long-standing member of the EACPT Board (1995-2015), including a position as vice-president (1999-2003).
  • Kim Brøsen served as secretary for the clinical division of IUPHAR (2000-08) of which he was a board member from 2006-14.
  • Kim Brøsen was president of the 5th EACPT Congress (2001) in Odense, Denmark, and the 1st IUPHAR World Congress (2010), Copenhagen, Denmark.
  • Kim Brøsen founded and led the Danish Clinical Intervention Research Academy from 2004-08.

Research

Kim Brøsen’s research has always been characterized by a deliberate and visible clinical approach in accordance with his position that clinical pharmacology as a medical speciality must strive to improve and support the medical treatment of patients. Kim Brøsen was among the true pioneers of pharmacogenomic research with numerous highly cited papers on the CYP2D6 polymorphism. Studies on imipramine metabolism and CYP2D6 polymorphism formed the basis of Kim Brøsen’s doctoral thesis in 1988. These studies resulted in one of his most important original discoveries that paroxetin is a strong in vivo inhibitor of CYP2D6 activity in humans. Kim Brøsen subsequentlyconducted a number of studies on the clinical relevance of CYP2D6 polymorphism to treatment with tricyclic antidepressants, especially imipramine and SSRIs, and opioids, especially codeine and tramadol.In recent years, Kim Brøsen has been increasingly involved in the role of drug transporters in human pharmacokinetics and -genomics. He is continuously providing substantial contributions to our understanding of the pharmacogenetics and -genomics of metformin, one of the most commonly prescribed antidiabetic drugs. Kim Brøsen has published more than 300 scientific papers as well as authored numerous national and international book chapters. He has been cited >10,000 times in the medical literature and has a CSI Hirsch Index of 57. Kim Brøsen has been the principal supervisor for more than 20 PhD students.

Conclusion

Kim Brøsen has been one of the most important contributors to the development of clinical pharmacology in Europe over the last 30 years. He has left clear and invaluable imprints on the practice, training, education, research and position of our discipline and professional trade. We believe the merits of Kim Brøsen naturally qualify him as a worthy recipient of the 2017 EACPT Lifetime Achievement Award.

The nomination letter was signed by

  1. Per Damkier Professor, MD, PhD
  2. Jesper Hallas Professor, MD, DMSc
  3. Morten Rix Hansen MD, Intern, clinical Pharmacology, PhD stud.

University of Southern Denmark
&
Odense University Hospital, Odense, Denmark
12 August 2016

view original nomination letter | 2nd nomination letter by DSKF | view letter of acceptance

[/wm_item]

[wm_item title=”Curriculum Vitae”]

Education
1981 Final University Examination in Medicine, University of Copenhagen
Postgraduate clinical training
1997- Consultant in clinical pharmacology, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital
1997: Specialist appointment in clinical pharmacology
1981-5 Intern in surgery, internal medicine, anaesthesiology and psychiatry
Scientific training and appointments
1995- Professor in human pharmacology with emphasis on pharmacogenetics, University of Southern Denmark in Odense
2002-3 Professeur Associé at Service de Pharmacologie, Hopital Saint-Antoine, Paris
1988-95 Associate professor in Clinical Pharmacology, Odense University
1988-9 Visiting associate professor at the Biocenter of the University of Basel, Switzerland 1986-8 Assistant professor in Clinical Pharmacology, Odense University
1985-6 Research assistant in Clinical Pharmacology, Odense University
University politics
1996-98 Pro-Vice-Chancellor (“Prorektor”) of Odense University
Honorary offices
2010 President of the 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010)
2006-14 Member of the Executive Committee, IUPHAR
2001 President of the 5th EACPT Congress, Odense Denmark
2000-8 Secretary, Clinical Division, IUPHAR
1999-2003 Vice-chairman of EACPT
1997-2014 Chairman of the Professional Executive Committee of Pro.medicin.dk (previously Drug Catalogue or Infomatum A/S)
1996-99 Member of the Executive Committee of the Scandinavian Society of Clinical Psychopharmacology
1995-2007 Member of the Executive Committee of the European Association for Clinical Pharmacology and Therapeutics (EACPT) (Co-opted 2007-15)
Scientific Advisory Boards
1997-2015 Member of the International Scientific Advisory Board for 9 European Congresses of Clinical Pharmacology and Therapeutics (CPT) and 3 CPT World Congresses and one World Congress on Basic and Clinical Pharmacology
1987-2009 Member of the Management Committee of the COST B1, B15 and B25 Actions
Editorial boards
2001-7 Therapeutic Drug Monitoring
1994-2007 European Journal of Clinical Pharmacology and Therapeutics
Scientific assessment
Eleven times a member of the assessment committee for the evaluation of a professor in clinical pharmacology or pharmacogenetics (Sweden (n=6), Denmark (n=2), Finland (n=1), Norway (n=2) and Hong Kong (n=1)).
Scientific Tutorials
Supervisor of 15 completed diploma theses and 27 completed Ph.D. theses. Presently co-supervisor for two Ph.D students
Awards
2005 The Poulsson Award
1991 The Ole J. Rafaelsen Award in Biological Psychiatry
Doctoral thesis
1988 The relationship between imipramine metabolism and the sparteine oxidation polymorphism. Odense University
Editorships
2014 Brøsen K, Simonsen U, Kampmann JP, Thirstrup (eds). Basic and Clinical Pharmacology (In Danish) 2014, 5th Edition, FADL, Copenhagen, Denmark
2012 Co-author on “Clinical Pharmacology in Health Care, Teaching and Research”
(WHO, CIOMS and IUPHAR)
2010 Kampmann JP, Brøsen K, Simonsen U (eds). Basic and clinical Pharmacology (in Danish) 2010, 4th Edition, FADL, Copenhagen, Denmark
2007 Kampmann JP, Brøsen K, Simonsen U (eds). Basic and Clinical Pharmacology (in Danish) 2007, 3rd edition, FADL, Copenhagen, Denmark
2003- Editor-in-chief of “Basic & Clinical Pharmacology & Toxicology”
1999 Brosen K (ed.). A Guide to Training in Clinical Pharmacology in Europe 1999, Odense University Press, Odense, Denmark
1999 Kampmann JP, Brøsen K, Nielsen-Kudsk F and Nyborg N (eds.). Basic and Clinical Pharmacology 1999, 2nd edition, FADL, Copenhagen, Denmark
Publications
Author ID: 7005953102. ORCID id: orcid.org/0000-0001-8444-7835
Approximately 275 publications and textbook chapters including appr.185 original and review papers published in international scientific journals with peer review. Main topics:
pharmacokinetics, drug-drug interactions, drug metabolism and the CYP2C19 and CYP2D6 polymorphisms. Number of citations according to Web of Science (26 April 2016, all databases): 10.776. H-index: 59. Highlycited researcher in pharmacology between 2001-15:

[/wm_item]
[wm_item title=”Publications”]

  1. Brøsen K. Individuelle variationer i lægemidlers oksidative metabolisme. Ugeskr Læger 1984;13:955-9.
  2. Brøsen K, Gram LF, Schou J, Larsen NE, Thayssen P. Dextropropoxyphene kinetics after single and repeated oral doses in man. Eur J Clin Pharmacol 1985;29:79-84.
  3. Brøsen K, Otton SV, Gram LF. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 1985;57:357-60.
  4. Brøsen K, Gram LF, Klysner R, Bech P. Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics. Eur J Clin Pharmacol 1986;30:43-9.
  5. Brøsen K, Otton SV, Gram LF. Sparteine oxidation polymorphism – A family study. Br J Clin Pharmacol 1986;21:661-7.
  6. Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV. Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 1986;22:194-7.
  7. Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986;30:679-84.
  8. Brøsen K. Sparteine oxidation polymorphism in Greenlanders living in Denmark. Br J Clin Pharmacol 1986;22:415-9.
  9. Brøsen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986;40:543-9.
  10. Gram LF, Brøsen K, Christensen P, Kragh-Sørensen P. Pharmacokinetic considerations relevant to the pharmacodynamics of antidepressants. In: Dahl SG, Gram LF, Paul SM, Potter WZ (eds): Clinical Pharmacology in Psychiatry. Springer Verlag 1987, pp. 184-92.
  11. Brøsen K, Gram LF, Haghfelt T, Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 1987;60:312-4.
  12. Gram LF, Brøsen K. Polymorphisme génétique de l’oxydation des médicaments psychotropes. Acta Med Inter Psychiatrie 1987;4:1368-74.
  13. Brøsen K. Farmakokinetik og grundlaget for lægemiddeldosering og terapikontrol. Månedsskr Prakt Lægeger 1987;65:889-96.
  14. Davidsen F, Haghfelt T, Gram LF, Brøsen K. Adverse drug reactions and drug non-compliance as primary cause of admission to a cardiology department. Eur J Clin Pharmacol 1988;34:83-6.
  15. Brøsen K, Gram LF. First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1988;43:400-6.
  16. Brøsen K. Farmakogenetik. Månedsskr Prakt Lægeger 1988;66:487-93.
  17. Brøsen K. The relationship between imipramine metabolism and the sparteine oxidation polymorphism. (Thesis). Dan Med Bull 1988;35:460-8.
  18. Drøhse A, Bathum L, Brøsen K, Gram LF. Mephenytoin and sparteine oxidation: Genetic polymorphisms in Denmark. Br J Clin Pharmacol 1989;27:620-5.
  19. Rotwitt LB, Rosholm J-U, Brøsen K, Gram LF. Art og omfang af lægemiddelinformation til alment praktiserende læger. Ugeskr Læger 1989;151:647-50.
  20. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-47.
  21. Brøsen K, Gram LF. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol 1989;37:155-60.
  22. Sindrup SH, Ejlertsen B, Frøland A, Sindrup EH, Brøsen K, Gram LF. Imipramine treatment in diabetic neuropathy: Relief of subjective symptoms without changes in measures of peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989;37:151-3.
  23. Gram LF, Brøsen K, Kragh-Sørensen P, Christensen P. Steady-state levels of E- and Z-10-OH-nortriptyline in nortriptyline treated patients: Significance of concurrent medication and the sparteine oxidation phenotype. Ther Drug Monit 1989;11:508-14.
  24. Gram LF, Brøsen K. Genetic polymorphism in drug oxidation: Implications for the clinical use of tricyclic antidepressants. In: Lerer B, Gershon S (eds): New directions in affective disorders. Springer Verlag 1989, p. 623-7.
  25. Brøsen K, Gram LF. Pharmacokinetic and clinical significance of genetic variability in psychotropic drug metabolism. In: Dahl SG, Gram LF (eds): Clinical Pharmacology in Psychiatry: Molecular Studies to Clinical Reality. Springer Verlag 1989, p. 192-200.
  26. Gram LF, Brøsen K. Inhibitors of the microsomal oxidation of psychotropic drugs: Selectivity and clinical significance. In: Dahl SG, Gram LF (eds): Clinical Pharmacology in Psychiatry: Molecular Studies to Clinical Reality. Springer Verlag 1989, p. 172-80.
  27. Gram LF, Brøsen K. Conditions under which genetic polymorphisms are clinically relevant. In: Alván G et al. (eds): “Consensus Conference on Pharmacogenetics”, Besançon 24-25 October 1989. Office for Official Publications of the European Communities, Luxemburg 1990, p. 87-96.
  28. Brøsen K, Davidsen F, Gram LF. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Br J Clin Pharmacol 1990;29:248-53.
  29. Brøsen K. Recent developments in hepatic drug oxidation – implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-39.
  30. Nielsen MD, Brøsen K, Gram LF. A dose-effect study on the in vivo inhibitory effect of quinidine on the sparteine oxidation in man. Br J Clin Pharmacol 1990;29:299-304.
  31. Danish University Antidepressant Group (DUAG). Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disord 1990;18:289-99.
  32. Hallas J, Harvald B, Gram LF, Grodum E, Brøsen K, Haghfelt T, Damsbo N. Drug related hospital admissions. The role of definitions and intensity of data collection, and the possibility of prevention. J Int Med 1990;228:83-90.
  33. Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-44.
  34. Zeugin TB, Brøsen K, Meyer UA. Determination of imipramine and seven of its metabolites in human liver microsomes by a high performance liquid chromatographic method. Anal Biochem 1990;189:99-102.
  35. Sindrup SH, Brøsen K, Gram LF. Non-linear kinetics of imipramine in low and medium plasma level ranges. Ther D Monit 1990;12:445-9.
  36. Sindrup SH, Gram LF, Skjold T, Grodum E, Brøsen K, Beck-Nielsen H. Clomipramine versus desipramine versus placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol 1990;30:683-91.
  37. Sindrup SH, Brøsen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, Gram LF. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not in poor metabolizers of sparteine. Clin Pharmacol Ther 1990;48:686-93.
  38. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23.
  39. Brøsen K. Cytokrom P450 gen-superfamiliens betydning for lægemidlers kliniske farmakokinetik. Ugeskr Læger 1991;153:417-22.
  40. Petersen P, Brøsen K. Svær nortriptylin-forgiftning hos langsom omdanner af spartein-typen. Ugeskr Læger 1991;153:443-4.
  41. Jensen J, Nielsen LH, Lyhne N, Hallas J, Brøsen K, Gram LF. Drugs and femoral neck fracture – a case-control study. J Int Med 1991;229:29-33.
  42. Brøsen K, Zeugin TB, Meyer UA. Role of P450IID6, the target of the sparteine/debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991;49:609-17.
  43. Clasen K, Madsen L, Brøsen K, Albøge K, Misfeldt S, Gram LF. Sparteine and mephenytoin oxidation: Genetic polymorphisms in East- and West Greenland. Clin Pharmacol Ther 1991;49:624-31.
  44. Brøsen K, Gram LF, Kragh-Sørensen P. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine and mephenytoin. Ther Drug Monit 1991;13:177-82.
  45. Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism – a panel study. Br J Clin Pharmacol 1991;31:689-92.
  46. Rask PH, Krarup G, Kragh-Sørensen P, Andersen E, Brøsen K et al. Terapistyring af perfenazinbehandling ved paranoide tilstande – organisatoriske aspekter. Ugeskr Læger 1991;153:2336-9.
  47. Kjeldsen CS, Larsen NE, Kragh-Sørensen P, Andersen E, Brøsen K et al. Terapistyring af perfenazinbehandling ved paranoide tilstande. Kliniske aspekter. Ugeskr Læger 1991;153:2339-43.
  48. Brøsen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 – the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991;32:136-7.
  49. Hallas J, Worm J, Beck-Nielsen J, Gram LF, Grodum E, Damsbo N, Brøsen K. Drug related events and drug utilization in patients admitted to a geriatric hospital department. Dan Med Bull 1991;38:417-20.
  50. Brøsen K, Secher B (red.). Lægemiddelinformation 1991. (Udgivet af Lægemiddeludvalget, Odense Sygehus).
  51. Hallas J, Gram LF, Grodum E, Damsbo N, Brøsen K et al. Drug related admissions to medical wards: A population based survey. Br J Clin Pharmacol 1992;33:61-8.
  52. Gram LF, Brøsen K, Sindrup SH, Skjelbo E. Clinical relevance of genetic polymorphisms in drug oxidation. In: Brès J, Davis G (eds): Pharmacocinétique: De la recherche à la clinique. John Libbeys Eurotext 1992, p. 40-7.
  53. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-87.
  54. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine – Nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
  55. Brøsen K. Lægemiddelinteraktioner. I: Kristensen MB, Bundgaard H, Jensen K (eds). Lægemiddelkataloget 1992:373-400.
  56. Sindrup SH, Arendt-Nielsen L, Brøsen K, Bjerring P, Angelo HR, Eriksen B, Gram LF. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol 1992;42:587-92.
  57. Sindrup SH, Tuxen C, Gram LF, Grodum E, Skjold T, Brøsen K, Beck-Nielsen H. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992;43:251-5.
  58. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
  59. Nielsen KK, Brøsen K, Gram LF, DUAG. Steady-state plasma levels of clomipramine and its metabolites: Impact of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1992;43:405-11.
  60. Brøsen K, Sindrup SH, Skjelbo E, Nielsen KK, Gram LF. Clinical relevance of genetic polymorphism in the oxidation of psychotropic drugs. In: Laux G and Riederer P (eds). Plasma Spiegel Bestimmung von Psychopharmaka. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1992, p. 19-20.
  61. Brøsen K. Variability in kinetics and response in humans. The Toxicology Forum, 1992, Annual European Meeting, Copenhagen, Denmark, June 1-5. CASET Associates Ltd., 3927 Old Lee Highway, Fairfax, VA 22030, USA, p. 451-63.
  62. Sindrup SH, Bjerre U, Dejgaard A, Brøsen K, Aaes-Jørgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-52.
  63. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphism. Ther Drug Monit 1993;15:11-7.
  64. Gram LF, Hansen MGJ, Sindrup SH, Brøsen K, Poulsen JH, Aaes-Jørgensen T, Overø KF. Citalopram: Interaction studies with levomepromazine, imipramine and lithium. Ther Drug Monit 1993;15:18-24.
  65. Nielsen KK, Brøsen K. High Performance Liquid Chromatography of imipramine and six metabolites in human plasma and urine. J Chromatogr 1993;612:87-94.
  66. Gram LF, Brøsen K, Sindrup SH, Skjelbo E. Risk factors in elderly taking psychotropic drugs: Significance of genetic polymorphism in drug oxidation. Nord J Psychiatry (suppl.) 1993;28:85-9.
  67. Brøsen K, Sindrup SH, Skjelbo E, Nielsen KK, Gram LF. Role of genetic polymorphism in psychopharmacology – an update. In: Gram LF, Balant LP, Meltzer HY, Dahl SG (eds). Proceedings of the “6th International Meeting on Clinical Pharmacology in Psychiatry”, Geneva, June 5-7 1991, p. 199-211.
  68. Skjelbo E, Gram LF, Brøsen K. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). – A population study. Br J Clin Pharmacol 1993;35:331-4.
  69. Nielsen KK, Brøsen K. High Performance Liquid Chromatography of clomipramine and metabolites in human plasma and urine. Ther Drug Monit 1993;15:122-8.
  70. Stage K, Brøsen K. Manglende effekt af nortriptylin hos en hurtig omdanner af spartein. Ugeskr Læger 1993;155:1561-3.
  71. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
  72. Brøsen K, Hansen MGJ, Kramer Nielsen K, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
  73. Sindrup SH, Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 1993;53:335-9.
  74. Gram LF, Brøsen K. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 1993;35:649-52.
  75. Brøsen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993;36:105-8.
  76. Brøsen K, Kragh-Sørensen P. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 1993;15:258-60.
  77. Brøsen K. Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions. Nordic J Psychiat 1993;47(suppl.39):21-6.
  78. DUAG. Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disord 1993;28:105-16.
  79. Ranek L, Dalhoff K, Poulsen HE, Brøsen K, Flachs H, Loft S. Wantzin P. Drug metabolism and genetic polymorphism in subjects with previous halothane hepatitis. Scand J Gastroenterol 1993;28(8):677-80.
  80. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 1993;71:1002-9.
  81. Brøsen K. CYP2D6-genotypebestemmelse. Ugeskr Læger 1993;155/46:3779-80.
  82. Brøsen K. (red.). Lægemiddelinformation 1994. (Udgivet af Lægemiddeludvalget, Odense Universitetshospital).
  83. Brøsen K. Farmakogenetik, Kap. 4 I: Kampmann JP et al. (eds): Basal og Klinisk Farmakologi (FADL 1994).
  84. Nielsen KK, Brøsen K, Hansen MGJ, Gram LF. Single dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55:518-27.
  85. Brøsen K, Nielsen PN, Brusgaard K, Gram LF, Skjødt K. CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 1994;47:221-5.
  86. Nielsen F, Nielsen KK, Brøsen K. Determination of quinidine, dihydroquinidine, (3S)-3-hydroxyquinidine, and quinidine-N-oxide in plasma and urine by high-performance liquid chromatography. J Chromatogr 1994;B660:103-10.
  87. Nielsen KK, Brøsen K, Hansen MGJ, Gram LF. Glucuronidation clearance of 8-hydroxyclomipramine in relation to the sparteine and mephenytoin phenotype. Eur J Clin Pharmacol 1994;47:209-10.
  88. Rasmussen BB, Nielsen KK, Brøsen K. Determination of theophylline metabolites in human liver microsomes by high-performance liquid chromatography. Anal Biochem 1994;222:9-13.
  89. Basçi NE, Brøsen K, Bozkurt A, Isimer A, Sayal A, Kayaalp SO. S-mephenytoin, sparteine and debrisoquine oxidation: Genetic polymorphisms in the Turkish population. Br J Clin Pharmacol 1994;38:463-5.
  90. Brøsen K. Øger langtidsbehandling med omeprazol risikoen for cancer? Ugeskr Læger 1994;41:6017-8.
  91. Poulsen L, Arendt-Nielsen L, Brøsen K, Nielsen KK, Gram LF, Sindrup SH. The hypoalgesic effect of imipramine in different human experimental pain models. Pain 1995;60:287-93.
  92. Rasmussen BB, Mäenpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
  93. Madsen H, Nielsen KK, Brøsen K. Imipramine metabolism in relation to the sparteine and the mephenytoin oxidation polymorphisms. Br J Clin Pharmacol 1995;39:433-9.
  94. Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K. Moclobemide – A substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2. – A panel study. Clin Pharmacol Ther 1995;57:670-7.
  95. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995;5:312-7.
  96. Nielsen F, Rosholm J-U, Brøsen K. Lack of relationship between quinidine pharmacoki-netics and the sparteine oxidation polymorphism. Eur J Clin Pharmacol 1995;48:501-4.
  97. Brøsen K. Drug interactions and the cytochrome P450 system. The role of cytochrome P4501A2. Clin Pharmacokinet 1995;29C(suppl.1):20-5.
  98. Brøsen K. Specific inhibitors of enzymes of drug metabolism. In: COST B1 conference on variability and specificity in drug metabolism. Eds: Alván G et al. 1995, p. 159-67.
  99. Gram LF, Brøsen K, Sindrup S, Skjelbo E. Genetic and interethnic variability in drug metabolism: What are the clinical consequences? In: COST B1 conference on variability and specificity in drug metabolism. Eds: Alván G et al. 1995, p. 235-45.
  100. Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995;5:335-46.
  101. Brøsen K, Rasmussen BB. Selective serotonin re-uptake inhibitors: Pharmacokinetics and drug interactions. In: J.P. Feighner and W.F. Boyer (eds.) Selective Serotonin Re-uptake Inhibitors: Advances in Basic Research and Clinical Practice. Second Edition, John Wiley & Sons Ltd. 1996, pp. 87-108.
  102. Sindrup SH, Hofmann U, Asmussen J, Mikus G, Brøsen K, Nielsen F, Ingwersen SH, Broen Christensen C. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. Eur J Clin Pharmacol 1996;49:503-9.
  103. Rasmussen BB, Brøsen K. Determination of theophylline and its metabolites in human urine and plasma by high-performance liquid chromatography. J Chromatogr, Biomed. Applications 1996;676:169-74.
  104. Rasmussen BB, Brøsen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 1996;18:254-62.
  105. Skjelbo E, Mutabingwa TK, Bygbjerg I, Nielsen KK, Gram LF, Brøsen K. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996;59:304-11.
  106. Nielsen KK, Flinois JP, Beaune P, Brøsen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996;277:1659-64.
  107. Brøsen K. Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 1996;11:23-7.
  108. Jeppesen U, Loft S, Poulsen HE, Brøsen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-22.
  109. Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996;18:393-6.
  110. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
  111. 1.* Poulsen L, Arendt-Nielsen, L, Brøsen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60:636-44.
  112. Madsen H, Hansen TS, Brøsen K. Imipramine metabolism in relation to the sparteine oxidation polymorphism – a family study. Pharmacogenetics 1996;6:513-9.
  113. Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF, Elbæk K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996;51:289-95.
  114. Brøsen K, Skjelbo E, Nielsen KK. Imipramine: a model drug for P450 research. In: Johnson EF, Waterman MR (eds.): Methods in Enzymology, vol 272, 1996, p. 177-86.
  115. Sonne J, Christensen HR, Gram LF, Kampmann JP, Brøsen K. Dansk statusartikel om klinisk farmakologi. Ugeskr Læger 1996/7.
  116. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol 1997;51:389-93.
  117. Rasmussen BB, Jeppesen U, Gaist D, Brøsen K. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Ther Drug Monit 1997;19:56-62.
  118. Madsen H, Rasmussen BB, Brøsen K. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19 and CYP3A4. Clin Pharmacol Ther 1997;61:319-24.
  119. Rasmussen BB, Brøsen K. Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans. Br J Clin Pharmacol 1997;43:253-8.
  120. Sindrup SH, Poulsen L, Brøsen K. Pain modulation and the genetic polymorphic enzyme CYP2D6. Analgesia 1996;2:259-65.
  121. Poulsen L, Arendt-Nielsen L, Brøsen K, Gram LF, Sindrup SH. Different effect of naloxone on pain perception in extensive and poor metabolizers of sparteine? Analgesia 1996;2:255-8.
  122. Madsen H, Møller Rasmussen J, Brøsen K. Interaction between tramadol and phenprocoumon. The Lancet 1997;350:637.
  123. Madsen H, Møller Rasmussen J, Brøsen K. Author’s reply. Lancet 1997;350:1553.
  124. Jeppesen U, Møller Rasmussen J, Brøsen K. Clinically important interaction between azathioprine (Imurel®) and phenprocoumar (Marcoumar®). Eur J Clin Pharmacol 1997;52:503-4.
  125. Jeppesen U, Rasmussen BB, Brøsen K. Fluvoxamine inhibits the CYP2C19 catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997;62:279-86.
  126. Bathum L, Hansen TS, Hørder M, Brøsen K. A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2 and CYP2C19*3 alleles involving time-resolved fluorometry. Ther Drug Monit 1998;20:1-6.
  127. Christensen PM, Gøtzsche P, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson’s disease: a meta-analysis. Pharmacogenetics 1998;8:473-9.
  128. Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, Brøsen K. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 1998;8:119-23.
  129. Skjelbo E, Brøsen K. En interaktion imellem paroxetin og clomipramin som mulig årsag til indlæggelse på medicinsk afdeling. Ugeskr Læger 1998;160:1257-58.
  130. Hansen LL, Larsen JT, Brøsen K. Determination of tacrine and its metabolites in human plasma and urine by high-performance liquid chromatography and fluorescence detection. J Chromatogr B 1998;712:183-91.
  131. Poulsen L, Riishede L, Brøsen K, Clemensen S, Sindrup SH. Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. Eur J Clin Pharmacol 1998;54:451-4.
  132. Andersen M, Arnberg A, Brøsen K, Gram LF, Petersen KB. Lægemiddelinformationscentralen ved Center for Klinisk Farmakologi i Odense. Ugeskr Læger 1998;60:3234.
  133. Bathum L, Andersen-Ranberg K, Boldsen J, Brøsen K, Jeune B. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity. Eur J Clin Pharmacol 1998;54:427-30.
  134. Sindrup SH, Brøsen K. Kombinationspræparater af codein og paracetamol. Ugeskr Læger 1998;160(4):448-9.
  135. Rasmussen BB, Nielsen TL, Brøsen K. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 1998;83:240-5.
  136. Brøsen K. Differences in interactions of SSRIs. Int J Clin Psychopharmacol 1998;13(suppl.5):S45-7.
  137. Buur Rasmussen B, Nielsen TL, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalyzed metabolism of proguanil in vitro. Eur J Clin Pharmacol 1998;54:735-40.
  138. Kortunay S, Bozkurt A, Bathum L, Basçi NE, Calgüneri M, Brøsen K, Kayaalp SO. CYP2D6 polymorphism in systemic lupus erythematosus patients. Eur J Clin Pharmacol 1999;55:21-5.
  139. Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, Brøsen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolisers of sparteine. Pharmacogenetics 1999;9:55-60.
  140. Danish University Antidepressant Group (DUAG). Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clin Pharmacol Ther 1999;66(2):152-65.
  141. Nielsen TL, Rasmussen BB, Flinois J-P, Beaune P, Brøsen K. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 1999;289:31-7.
  142. Brøsen K (edt.). A Guide to Training in Clinical Pharmacology in Europe. European Association for Clinical Pharmacology and Therapeutics. Odense University Press 1999, pp. 340.
  143. Brøsen K. Klinisk farmakologi – hvad skal vi med det? Ugeskr Læger 1999;161/26:3981.
  144. Teilmann Larsen J, Lindal Hansen L, Spigset O, Brøsen K. Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. Eur J Clin Pharmacol 1999;55:375-82.
  145. Damkier P, Hansen LL, Brøsen K. Effect of fluvoxamine on the pharmacokinetics of quinidine. Eur J Clin Pharmacol 1999;55:451-56.
  146. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brøsen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1999;290:635-40.
  147. Kortunay S, Bozkurt A, Bathum L, Basci NE, Calguneri M, Brøsen K, Kayaalp SO. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. Ann Rheum Dis 1999;58:182-5.
  148. Senderovitz T, Heisterberg J, Christophersen B. Kompendium i farmakologi. FADLs Forlag 1999, pp. 283. Boganmeldelse af K. Brøsen. I: Ugeskr Læger 1999;161/34:4755.
  149. Brøsen K, Kampmann JP. Metoder i klinisk farmakologisk forskning (inkl. GCP). I: Sundhedsvidenskabelig Forskning. Andersen D et al. (eds.). FADLs Forlag 1999, p. 427-58.
  150. Bathum L, Skjelbo E, Mutabingwa TK, Madsen K, Hørder M, Brøsen K. Pheno- and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 1999;48:395-401.
  151. Damkier P, Hansen LL, Brøsen K. Rifampicin treatment greatly increases the apparent oral clearance of quinidine. Pharmacol Toxicol 1999;85:257-62.
  152. Larsen JT, Hansen LL, Brøsen K. Tacrine is probably not an ideal probe drug for measuring CYP1A2 activity in vivo. Br J Clin Pharmacol 1999;48:663-8.
  153. Damkier P, Hansen LL, Brøsen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999;48:829-38.
  154. Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB. Basal og Klinisk Farmakologi. 2. udgave, FADL’s Forlag 1999, pp. 806.
  155. Brøsen K. Lægemidlers skæbne i organismen. Kap. 3. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red. Basal og Klinisk Farmakologi. 2. udgave, FADL’s Forlag 1999, p. 33-58.
  156. Brøsen K. Lægemidlers elimination. Kap. 4. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave, FADL’s Forlag 1999, p. 59-71.
  157. Brøsen K. Farmakogenetik. Kap. 5. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave, FADL’s Forlag 1999, p. 73-77.
  158. Brøsen K, Christensen HR. Lægemiddelinteraktioner. Kap. 59. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave. FADL’s Forlag 1999, p. 667-71.
  159. Madsen H, Brøsen K. Lægemidler og graviditet. Kap. 63. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave. FADL’s Forlag 1999, p. 705-14.
  160. Brøsen K. Styret terapi. Kap. 67. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave. FADL’s Forlag 1999, p. 743-46.
  161. Brøsen K, Kampmann JP. Klinisk afprøvning af lægemidler. Kap. 68. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave. FADL’s Forlag 1999, p. 747-55.
  162. Buur Rasmussen B, Brøsen K. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 1999;9:453-9.
  163. Hansen LL, Brøsen K. Quantitative determination of tolbutamide and its metabolites in human plasms and urine by high-performance liquid chromatography and UV detection. Ther Drug Monit 1999;21:669-71.
  164. Sindrup SH, Madsen C, Brøsen K, Jensen TS. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin Pharmacol Ther 1999;66:636-41.
  165. Sindrup SH, Andersen G, Madsen C, Smith T, Brøsen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy. A randomized, double-blind, controlled trial. Pain 1999;83:85-90.
  166. . Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimising clinical outcome and avoiding interactions of the selective serotonin re-uptake inhibitors? Ther Drug Monit 2000;22:143-54.
  167. Brøsen K. Etniske variationer med hensyn til genetisk polymorfi I metabolismen af lægemidler. Ugeskr Læger 2000;162:818.
  168. Brøsen K. Antiarrhythmics. Chapter 45. In: Metabolic Drug Interactions (Levy RH et al., eds.). Lippincott, Williams & Wilkins 2000, Philadelphia, USA, p. 603-14.
  169. Damkier P, Brøsen K. Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19 and CYP2D6. Clin Pharmacol Ther 2000;68:199-209.
  170. Justesen US, Brøsen K, Pedersen C. Hiv-proteasehæmmere og interaktioner. Ugeskr Læger 2000;162:4677-81.
  171. Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjöqvist F, Spina E, Brockmöller J. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-92.
  172. Larsen J, Arnberg A, Brøsen K. Tramadol og oxazepam. Ugeskr Læger 2001;163:458-60.
  173. Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brøsen K. Fluvoxamine inhibits the CYP2C19 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 2001;69:41-7.
  174. Bergmann TK, Bathum L, Brøsen K. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. Eur J Clin Pharmacol 2001;57:123-7.
  175. Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001); 11:275-283.
  176. Brøsen K, Nedergaard OA, Orme. Abstract Book 5th EACPT Congress. Pharmacol Toxicol 89, suppl I, 2001.
  177. Larsen JT, Clemensen SV, Klitgaard NA, Nielsen B, Brøsen K. Clozapine-induced toxic hepatitis. Ugeskr Laeger 2001; 163(14): 2013-4.
  178. Kortunay S, Bozkurt A, Basci NE, Brøsen K, Kayaalp SO. Dose-dependent inhibition of the CYP2D6 catalyzed oxidation of sparteine by mepyramine in healthy volunteer. Pharmacol Toxicol 2001;89:331-4.
  179. Christensen PM, Brøsen K, Brixen KT, Beck-Nielsen H, Søgaard J, Kristiansen IS. Farmakoøkonomisk evalueringer af medicinsk behandling af osteoporose. Ugeskr Laeger 2002;164:1339-45.
  180. Jürgens G, Lange KH, Reuther L, Rasmussen BB, Brøsen K, Christensen HR. Effect of growth hormone on hepatic cytochrome P450 activities in healthy elderly men. Clin Pharmacol Ther 2002; 71:162-8.
  181. Jürgens G, Christensen HR, Brøsen K, Sonne J, Loft S, Olsen NV. Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. Clin Pharmacol Ther 2002; 71:214-20
  182. Rasmussen BB, Brix TH, Kyvik KO, Brøsen K. The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002; 12:473-8
  183. Breinholt VM, Offord EA, Brouwer C, Nielsen SE, Brøsen K, Friedberg T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol 2002;40:609-16
  184. Christensen PM, Brøsen K, Brixen K, Kristiansen IS. Expressing effects of osteoporosis interventions in terms of postponing fractures. Eur J Clin Pharmacol 2002;58:629-33
  185. Justesen US, Klitgaard NA, Brøsen K, Pedersen C. Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 2003;55:100-6
  186. Pedersen RS, Brøsen K, Nielsen F. Enantioselective HPLC method for qunatitative determination of tramadol and O-desmethyltramadol in plasma and urine: Application to clinical studies. Chromatrographia 2003;57:279-85.
  187. Breinholt VM, Rasmussen SE, Brøsen K, Friedberg TH. In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s. Pharmacol Toxicol. 2003; 93:14-22.
  188. Christensen PM, Brøsen K, Brixen K, Andersen M, Kristiansen IS. A randomized trial of laypersons’ perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. Clin Ther 2003;25:2575-85.
  189. Brøsen K Pharmacol Toxicol. Letter from the editor. 2004;94:1-2.
  190. Pedersen RS, Verstuyft C, Becquemont L, Jaillon P, Brøsen K. Cytochrome P4502C9 (CYP2C9) Genotypes in a Nordic Population in Denmark. Bas Clin Pharmacol Toxicol. 2004; 94:151-2.
  191. Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, Brøsen K. Rifampicin seems to act both an inducer end an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 2004;60:109-14
  192. Justesen US, Klitgaard NA, Brøsen K, Pedersen C. Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. J Antimicrob Chemother 2004;
  193. Justesen US, Andersen AB, Klitgaard NA, Brøsen K, Gerstoft J, Pedersen C. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Infect Dis. 2004;38:426-9.
  194. Brøsen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 2004; 59:5-12
  195. Brøsen K. Letter from the editor. Basic Clin Pharmacol Toxicol. 2005; 96:1-2
  196. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH and Brøsen K. Paroxetine, a cytochrome P4502D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005;77:312-23
  197. Brøsen K. Klassisk farmakogenetik. Ugeskr Læger 2005;167:2143-6
  198. Madsen H, Brøsen K, Frimodt-Møller N og Gahrn-hansen B. Antibiotika og overvægt. Ugeskr Læger 2005;167:2266-70
  199. Pedersen RS, Damkier P, Brøsen K. Tramadol as a probe for cytochrome P4502D6 phenotyping: A population study. Clin Pharmacol Ther 2005;77:458-67
  200. Teilmann Larsen J, Brøsen K. Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo. Bas Clin Pharmacol Toxicol 2005;97:141-8
  201. Pedersen RS, Brøsen K, Nielsen F. HPLC method for determination of rosiglitazone in plasma. Chromatographia 2005;62:197-201
  202. Halling J ,Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P, Lundgren S, Lundblad MS, Brøsen K. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol 2005;61:491-7
  203. Brøsen K. From the editor. Basic Clin Pharmacol Toxicol. 2005;97(4):201.
  204. Enggaard TP, Poulsen L, Arendt-Nielsen L, Brøsen K, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg. 2006;102(1):146-50.
  205. Bidstrup TB, Damkier P, Olsen AK, Ekblom M, Karlsson A, Brøsen K. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. Br J Clin Pharmacol. 2006;61:49-57.
  206. Skaalum Petersen M, Halling J, Damkier P, Nielsen F, Grandjean P, Weihe P and Brøsen K. Caffeine N3-demethylation (CYP1A2) in a population with increased exposure to polychlorinated biphenyls. Eur J Clin Pharmacol 2006;62:1041-8
  207. Pedersen RS, Damkier P, Brøsen K. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol. 2006 Dec;62(6):682-9. Epub 2006 Jul 12.
  208. Pedersen RS, Damkier P, Brøsen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol. 2006 Jul;62(7):513-21. Epub 2006 Jun 9
  209. Noehr-Jensen L, Damkier P, Bidstrup TB, Pedersen RS, Nielsen F, Brøsen K. The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers. Eur J Clin Pharmacol. 2006 Jun; 62(6):437-45. Epub 2006 Apr 28.
  210. Andreasen AH, Brøsen K, Damkier P. A Comparative Pharmacokinetic Study in Healthy Volunteers of the Effect of Carbamazepine and Oxcarbazepine on CYP3A4. Published article online: 4-Jan-2007 doi: 10.1111/j.1528-1167.2007.00924.x
  211. 1. Brøsen K. Kønsforskelle I farmakologien. Ugeskr Laeger 2007; 169(25): 2408-11
  212. Brøsen K. Lægemidlers skæbne i organismen. Kap 3 i: Kampmann JP, Brøsen K, Simonsen U: Basal og Klinisk Farmakologi 2007, 3. udgave, FADLs Forlag, København, p. 67-92.
  213. Brøsen K. Lægemidlers elimination. Kap 4 i: Kampmann JP, Brøsen K, Simonsen U: Basal og Klinisk Farmakologi 2007, 3. udgave, FADLs Forlag, København, p. 93-106.
  214. Brøsen K. Farmakogenetik/-genomik. Kap 5 i: Kampmann JP, Brøsen K, Simonsen U: Basal og Klinisk Farmakologi 2007, 3. udgave, FADLs Forlag, København, p. 107-112.
  215. Brøsen K, Christensen HR. Lægemidelinteraktioner. Kap 64 i: Kampmann JP, Brøsen K, Simonsen U: Basal og Klinisk Farmakologi 2007, 3. udgave, FADLs Forlag, København, p 717-22
  216. Brøsen K. Styret terapi. Kap 73 i: Kampmann JP, Brøsen K, Simonsen U: Basal og Klinisk Farmakologi 2007, 3. udgave, FADLs Forlag, København, p. 805-7.
  217. Brøsen K, Kampmann JP. Kap 74 i: Kampmann JP, Brøsen K, Simonsen U: Basal og Klinisk Farmakologi 2007, 3. udgave, FADLs Forlag, København, p. 809-18.
  218. Petersen MS, Halling J, Damkier P, Nielsen F, Grandjean P, Weihe P, Brøsen K. Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults. Toxicol Appl Pharmacol. 2007;224(2):202-6. Epub 2007 Jul 14
  219. Tfelt-Hansen P, Brøsen K. Pharmacogenomics and migraine: possible implications. J Headache Pain. 2008 Jan 24, DOI 10.1007/s10194-008-0009-y [Epub ahead of print].
  220. Halling J, Weihe P, Brøsen K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. Br J Clin Pharmacol. 2008;65(1):134-8. Epub 2007 Aug 31.
  221. 1.* Halling J, Petersen MS, Grandjean P, Weihe P, Brøsen K. Genetic predisposition to Parkinson’s disease: CYP2D6 and HFE in the Faroe Islands. Pharmacogenet Genomics. 2008 Mar;18(3):209-212.
  222. 2.* Kragelund C, Hansen C, Torpet LA, Nauntofte B, Brøsen K, Pedersen AM, Buchwald C, Therkildsen MH, Reibel J. Expression of two drug-metabolizing cytochrome P450-enzymes in human salivary glands. Oral Dis. 2008 Feb 10
  223. Kragelund C, Hansen C, Torpet LA, Nauntofte B, Brøsen K, Pedersen AM, Buchwald C, Therkildsen MH, Reibel J. Expression of two drug-metabolizing cytochrome P450-enzymes in human salivary glands. Oral Dis. 2008 Feb 10; [Epub ahead of print]
  224. Otto M, Bach FW, Jensen TS, Brøsen K, Sindrup SH. Escitalopram in painful polyneuropathy: A randomized, placebo-controlled, cross-over trial. Pain. 2008 [Epub ahead of print].
  225. Halling J, Weihe P, Brøsen K. CYP2D6 polymorphism in relation to tramadol metabolism: a study of Faroese patients. Ther Drug Monit. 2008 30(3):271-5.
  226. Vach W, Bergmann TK, Brøsen K. No evidence for taxane/platinum pharmacogen-etic markers: just lack of power? J Clin Oncol. 2008; 26(11):1903-4.
  227. Sorensen L, Nielsen B, Stage KB, Brøsen K, Damkier P. Implementation of a rational pharmacotherapy intervention for inpatients at a psychiatric department. Nord J Psychiatry. 2008;62(3):242-9.
  228. Kragelund C, Hansen C, Reibel J, Nauntofte B, Broesen K, Pedersen AM, Smidt D, Eiberg H, Torpet LA. Polymorphic drug metabolizing CYP-enzymes–a pathogenic factor in oral lichen planus? J Oral Pathol Med. 2009 Jan;38(1):63-71.
  229. Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, Brøsen K, Sindrup SH. The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation Polymorphism. Bas Clin Pharmacol Toxicol 2009; 104(4): 335-344.
  230. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Nielsen F, Brøsen K. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol. 2009 Sep;65(9):887-94. Epub 2009 Apr 29.
  231. Noehr-Jensen L, Zwisler ST, Damkier P, Larsen F, Brøsen K. Escitalopram is a weak inhibitor of the CYP2D6 catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. Clin Pharmacol Ther 2009 Dec;86(6):626-33. Epub 2009 Aug 26
  232. Zwisler ST, Mikkelsen S, Enggaard TP, Brøsen K, Sindrup SH. Impact of CYP2D6 genotype on postoperative intravenous oxycodone analgesia. Act Anaesth Scand 2010 Feb;54(2):232-40. Epub 2009 Aug 31.
  233. Zwisler ST, Enggaard TP, Noehr-Jensen L, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Brøsen K. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol 2010;24(4):517-24
  234. Kragelund C, Hansen C, Reibel J, Nauntofte B, Brøsen K, Jensen SB, Torpet LA. Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions? Journal of Oral Pathology 2010: 39(6);497-505
  235. Nielsen A, Pedersen R, Noehr-Jensen L, Damkier P, Brøsen K.Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol’s O-demethylation via CYP2D6. Eur J Clin Pharmacol 2010: 66(7); 655-60.
  236. Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, Weihe P, Edvardsen H, Kristensen VN, Brøsen K, Ingelman-Sundberg M. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 2010. Dec;66(12):1199-1205. Jul 28. [Epub ahead of print].
  237. Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L, Sir Rawlins M, Reidenberg M, Sjöqvist F, Smith T, Thuerman P, Walubo A. Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 2010;107(1):531-59.
  238. Kjærstad MB, Nielsen F, Nøhr-Jensen L, Zwisler S, Brøsen K, Andersen HR. Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. Eur J Clin Pharmacol. 2010 Dec;66(12):1189-1197. Epub 2010 Oct 6
  239. Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brøsen K. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 2010 Apr 6. [Epub ahead of print]
  240. Brøsen K. Lægemidlers skæbne i organismen. I: Basal og Klinisk Farmakologi 4. udg. FADL’s Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. s. 61-86
  241. Brøsen K. Lægemidlers elimination. I: Basal og Klinisk Farmakologi 4. udg. FADL’s Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. s. 87-99.
  242. Brøsen K. Farmakogenetik. I: Basal og Klinisk Farmakologi 4. udg. FADL’s Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. s. 101-6.
  243. Brøsen K, Christensen HR. Lægemiddelinteraktioner. I: Basal og Klinisk Farmakologi 4. udg. FADL’s Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. s.701-703.
  244. Brøsen K. Styret terapi. I: Basal og Klinisk Farmakologi 4. udg. FADL’s Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. S. 801-3
  245. Brøsen K, Christensen HR. Lægemiddelinteraktioner. I: Basal og Klinisk Farmakologi 4. udg. FADL’s Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. S. 807-14
  246. Bergmann TK, Gréen H, Brasch-Andersen C, Mirza MR, Herrstedt J, Hølund B, du Bois A, Damkier P, Vach W, Brøsen K, Peterson C. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol. 2011;67(7):693-700 Feb 16.
  247. Brøsen K. Lægemiddelinduceret hepatotoksicitet – glem ikke naturprodukter! Ugeskr Læger 2011;173(34):2028
  248. Brasch-Andersen C, Møller MU, Christiansen L, Thinggaard M, Otto M, Brøsen K, Sindrup SH. A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). Eur J Clin Pharmacol. 2011;67:1131-7
  249. Christensen MMH, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, Brøsen K. Metformin Plasma Steady-State Levels and Glycosylated Hemoglobin, A1c (HbA1c) in patients with type 2 diabetes: Impact of gene variants in PMAT, OCT1, OCT2, MATE1 and MATE2. Pharmacogenetics and Genomics 2011;21(12):837-850
  250. Zwisler ST, Enggaard TP, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Brøsen K. Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. J Clin Pharmacol. 2012; 52:234-242.
  251. Holmgaard R, Benfeldt E, Bangsgaard N, Sorensen JA, Brøsen K, Nielsen F, Nielsen JB. Probe Depth Matters in Dermal Microdialysis Sampling of Benzoic Acid after Topical Application: An ex vivo Study in Human Skin. Skin Pharmacol Physiol 2012; 25:9-16 (DOI: 10.1159/000330491)
  252. Bergmann TK, Andersen CB, Gréen H, Mirza MR, Skougaard K, Wihl J, Keldsen N, Damkier P, Peterson C, Vach W, Brøsen K. Impact of ABCB1 Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer. Basic Clin Pharmacol Toxicol. 2012; 110: 199-204.
  253. Brøsen K. BCPT Nordic Prize in Basic & Clinical Pharmacology & Toxicology for 2011 to Pertti J. Neuvonen. Basic Clin Pharmacol Toxicol 2012 Mar;110(3):205-6. Doi: 10.1111/j.1742-7843.2012.00859.x.
  254. Pedersen RS, Christensen MM, Brøsen K. Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. Eur J Clin Pharmacol 2012; 68(10):1463-4.
  255. Brøsen K. Letter from the editor. Basic Clin Pharmacol Toxicol 2012 Dec;111(6):361. doi: 10.1111/bcpt.12030.
  256. Bergmann TK, Vach W, Feddersen S, Eckhoff L, Gréen H, Herrstedt J, Brøsen K. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol. 2013 52(4):871-4. doi: 10.3109/0284186X.2012.707787
  257. Stage TB, Christensen MM, Feddersen S, Beck-Nielsen H, Brøsen K. The role of genetic variants in CYP2C8, LPIN1, PPARGCA and PPARy on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenet Genomics 2013; 23(4):219-27. doi: 10.1097/FPC.0b013e32835f91fc.
  258. Brøsen K. Letter from the editor. Basic Clin Pharmacol Toxicol 2013 Jan;112(1):1.doi: 10.1111/bcpt.12040.
  259. Brøsen K. BCPT Nordic Prize in Basic and Clinical Pharmacology and Toxicology for 2012 to Michael J. Mulvany. Basic Clin Pharmacol Toxicol. 2013 May;112(5):287-8. doi: 10.1111/bcpt.12053.
  260. Pedersen RS, Noehr-Jensen L, Brosen K. The inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele. Clin Exp Pharmacol Physiol. 2013;40(10):683-8. doi: 10.1111/1440-1681.12153.
  261. Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P, Beck-Nielsen H, Brøsen K. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics. 2013 Oct;23(10):526-34. doi: 10.1097/FPC.0b013e328364a57d
  262. Pedersen RS, Noehr-Jensen L, Brosen K. The inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele. Clin Exp Pharmacol Physiol. 2013;40(10):683-8. doi: 10.1111/1440-1681.12153.
  263. Pedersen RS, Damkier P, Christensen MM, Brosen K. A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers. Eur J Clin Pharmacol. 2013;69(12):1997-9
  264. Nielsen F, Christensen MMH, Brøsen K. Quantitation of Metformin in Human Plasma and Urine by Hydrophilic Interaction Liquid Chromatography and Application to a Pharmacokinetic Study. Ther D Monit 2014;36:211-7
  265. Pedersen RS, Nielsen F, Stage TB, Vinholt PJ, El-Achwah AB, Damkier P, Brosen K. CYP2C19*17 increases the clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. Clin Exp Pharmacol Physiol. 2014;441:870-8. doi: 10.1111/1440-1681.12297.
  266. Kragelund C. Jensen SB, Hansen C, Brosen K et. Al. Subgrouping of patients with oral lichen planus according to cytochrome P450 enzyme phenotype and genotype. Oral Surg Oral Med Oral Radiol 2014;118: 469-74
  267. Brøsen K. Lægemidlers skæbne I organismen. Kap 3, pp 55-84 i: “Basal og Klinisk Farmakologi”, Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014.
  268. Brøsen K. Lægemidlers elimination. Kap 4, pp 85-100 i: “Basal og Klinisk Farmakologi”, Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014.
  269. Brøsen K. Farmakogenetik/-genomik. Kap 5, pp101-8 i “Basal og Klinisk Farmakologi”, Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014
  270. Brøsen K, Christensen HR. Lægemiddelinteraktioner. Kap 5, pp 774-9 i: “Basal og Klinisk Farmakologi”, Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014.
  271. Damkier P, Brøsen K. Styret terapi og biomarkører. Kap 74, pp 873-7 i: “Basal og Klinisk Farmakologi”, Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014.
  272. Hallas J, Andersen M, Brøsen K. Lægemiddelforbrug. Kap 76, pp 888-91 i: “Basal og Klinisk Farmakologi”, Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014.
  273. Brøsen K, Damkier P. Genomet og farmakologien [The genome and Pharmacology. Ugeskr Laege 2014;176:2183-6
  274. Stage TB, Pedersen RS, Damkier P, Christensen MM, Feddersen S, Larsen JT, Højlund K, Brøsen K. Intake of St. John’s wort improves the glucose tolerance in healthy subjects that ingest metformin compared to metformin alone. Br J Clin Pharmacol 2015;79:298-306 doi: 10.1111/bcp.12510.
  275. Stage TB, Damkier P, Pedersen RS, Christensen MM, Christiansen L, Christensen K, Brosen K. A twin study of the trough plasma steady-state concentration of metformin. Pharmacogenet Genomics. 2015;25:259-62
  276. Holbech JV, Bach FW, Finnerup NB, Brøsen K, Jensen TS, Sindrup SH. Pain. 2015 Feb 19. Imipramine and Pregabalin Combination for Painful Polyneuropathy. A Randomized Controlled Trial. Pain. 2015 May;156(5):958-66. doi: 10.1097.
  277. Christoffersen DJ, Brasch-Andersen C, Thomsen JL, Worm-Leonhard M, Damkier P, Brøsen K. Quantification of morphine, morphine 6-glucuronide, buprenorphine, and the enantiomers of methadone by enantioselective mass spectrometric chromatography in whole blood. Forensic Sci Med Pathol. 2015 Jun;11(2):193-201. doi: 10.1007/s12024-015-9673-9. Epub 2015 Mar 24.
  278. Christensen MM, Højlund K, Hother-Nielsen O, Stage TB, Damkier P, Beck-Nielsen H, Brøsen K. Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur J Clin Pharmacol. 2015 Jun;71(6):691-7. doi: 10.1007/s00228-015-1853-8. Epub 2015 May 5.
  279. Brosen K. Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. Drug Metabol Personal Ther. 2015;30(3)_147-63. Jan 23. pii: /j/dmdi.ahead-of-print/dmdi-2014-0029/dmdi-2014-0029.xml. doi: 10.1515/dmdi-2014-0029.
  280. Stage TB, Brøsen K, Christensen MM. A Comprehensive Review of Drug-Drug Interactions with Metformin. Clin Pharmacokinet. 2015 54(8):811-24. doi: 10.1007/s40262-015-0270-6
  281. Lassen D, Damkier P, Brøsen K. The Pharmacogenetics of Tramadol. Clin Pharmacokinet. 2015 54(8):825-36. doi: 10.1007/s40262-015-0268-0.
  282. Lee MY, Apellániz-Ruiz M, Johansson I, Vikingsson S, Bergmann TK, Brøsen K, Green H, Rodríguez-Antona C, Ingelman-Sundberg M. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. Pharmacogenomics 2015 6(9):929-37. doi: 10.2217/pgs.15.46. Epub 2015 Jun 26.
  283. Apellaniz-Ruiz M, Sanchez-Barroso L, Gutierrez-Gutierrez G, Sereno M, García-Donas J, Åvall-Lundqvist E, Green H, Brøsen K, Bergmann TK, and Rodríguez-Antona C. Replication of genetic polymorphisms reported to be associated with taxane related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin Cancer Research 2015 21(13):3092-3. doi: 10.1158/1078-0432.CCR-14-1885.
  284. Brøsen K. Professor Olavi Pelkonen is the 2014 BCPT Nordic Prize Winner in Basic and Clinical Pharmacology and Toxicology. Basic Clin Pharmacol Toxicol. 2015 Sep;117(3):145-6
  285. Christensen MM, Højlund K, Hother-Nielsen O, Stage TB, Damkier P, Beck-Nielsen H, Brøsen K. Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial. Diabetologia. 2015 Nov;58(11):2494-502.
  286. Larsen JK, Krogh-Nielsen L, Brøsen K. The use of the monoamine oxidase inhibitor isocarboxazide in treatment-resistant depression]. Ugeskr Laeger. 2015 Dec 21;177(52).
  287. Stage TB, Pottegård A, Henriksen DP, Christensen MM, Højlund K, Brøsen K, Damkier P. Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study. J Thromb Haemost. 2016 Jan;14(1):129-33. doi:
  288. Stage TB, Damkier P, Christensen MM, Nielsen LB, Højlund K, Brøsen K. Impaired Glucose Tolerance in Healthy Men Treated with St. John’s Wort. Basic Clin Pharmacol Toxicol. 2015 2016 Mar;118(3):219-24. doi: 10.1111/bcpt.12486.
  289. Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K. Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. Br J Clin Pharmacol. 2016;81:313-5.
  290. Stage TB, Lee MP, Hallas J, Christensen MM, Brøsen K, Christensen K, Gagne JJ, Pottegård A. Early Discontinuation of Metformin in Individuals Treated with Inhibitors of Transporters of Metformin. Basic Clin Pharmacol Toxicol. 2016 Jun;118(6):487-95. doi: 10.1111/bcpt.12579. Epub 2016 Apr 25. PMID: 27128732
  291. Christoffersen DJ, Damkier P, Feddersen S, Möller S, Thomsen JL, Brasch-Andersen C, Brøsen K The ABCB1, rs9282564, AG and TT Genotypes and the COMT, rs4680, AA Genotype are less frequent in Deceased Patients with Opioid Addiction (DOA) than in Living Patients with Opioid Addiction (LOA). Basic Clin Pharmacol Toxicol. 2016 Apr 9. doi: 10.1111/bcpt.12602.
  292. Nguyen A, Stage TB, Feddersen S, Christoffersen DJ; Christensen MM, Damkier P; Thomsen JL, Brøsen K. Carriers of genetic variants in the HNF1A gene are more common among dead opioid addicts than among living addicts. Eur J Clin Pharmacol (accepted)

ResearcherID: F-6023-2011, Scopus Author ID: 7005953102, orcid.org/0000-0001-8444-7835.

Number of citations according to Web of Science (All databases, 26 May 2016): 10.794 H-index: 59. Highlycited researcher in pharmacology between 2001-15

* Original scientific papers or review papers in international scientific journals with peer review. Updated 26 May 2016

download complete list of publications

[/wm_item][/wm_tabs][/vc_column][/vc_row]